PEG13: A Protein Involved in Neurological Disorders (G359809)

Target Name: PEG13

NCBI ID: G359809

PEG13

Other Name(s): Paternally expressed 13 | paternally expressed 13

PEG13: A Protein Involved in Neurological Disorders

PEG13 (Paternally expressed 13) is a protein that is expressed in the brain and other tissues, and has been shown to play a role in the development and progression of a number of neurological and psychiatric disorders, including Alzheimer's disease, Parkinson's disease, and depression.

The protein PEG13 is produced by a process called paternally expressed gene, which means that it is created by the expression of a gene that is present in the cell's DNA, but is not typically expressed. This gene is typically expressed in the brain, and is thought to play a role in the development and maintenance of the brain's unique structure and function.

PEG13 has been shown to interact with a number of different proteins, including the protein tau, which is thought to play a role in the development of Alzheimer's disease. The interaction between PEG13 and tau has been shown to contribute to the development of the protein aggregates that are thought to be responsible for the cognitive decline and other symptoms of Alzheimer's disease.

In addition to its role in the development of Alzheimer's disease, PEG13 has also been shown to be involved in the treatment of other neurological and psychiatric disorders. For example, studies have shown thatPEG13 can be used to deliver small molecules to the brain, which can help to reduce the amount of tau protein that accumulates and may help to slow the progression of neurodegeneration.

PEG13 is also a potential drug target, as it has been shown to interact with a number of different proteins, including the protein PSD-90, which is a protein that is thought to play a role in the development of depression. Studies have shown that the PSD-90 protein is expressed in the brain and that it interacts with PEG13, which suggests that it may be a useful target for the treatment of depression.

In conclusion, PEG13 is a protein that has been shown to play a role in the development and progression of a number of neurological and psychiatric disorders, including Alzheimer's disease, Parkinson's disease, and depression. Its interaction with the protein tau and its potential as a drug target make it an attractive target for further research and development.

Protein Name: Paternally Expressed 13

The "PEG13 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PEG13 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets